MoonLake Immunotherapeutics (MLTX)

MoonLake Immunotherapeutics has reported concerning financial highlights for Q2 '25, with a gross profit of -740,000, reflecting a significant 96.3% change from the previous quarter. This negative gross profit indicates challenges in production efficiency and possibly declining sales performance. The cost of revenue was reported to be 740,000, another substantial 96.3% increase from the last quarter, suggesting that rising costs may be impacting the company’s margins significantly. While a higher cost of revenue could sometimes indicate aggressive scaling, the lack of revenue growth in tandem raises alarms about the sustainability of current operations. Interestingly, social media mentions have surged by 59.1% in the past 24 hours, indicating a potential increase in public interest or sentiment towards the company, which could provide a narrative shift if it translates into future revenue growth.